Kernicterus (Bilirubin‑Induced Neurologic Dysfunction)
What is Kernicterus (Bilirubin‑Induced Neurologic Dysfunction)?
Kernicterus, also called bilirubin‑induced neurologic dysfunction (BIND), is a rare but serious form of brain injury that occurs when very high levels of unconjugated bilirubin cross the blood‑brain barrier and deposit in specific brain regions, most notably the basal ganglia, hippocampus, and brainstem. The condition is most commonly seen in newborn infants whose livers are not yet fully capable of processing bilirubin, but it can also occur in older children and adults with severe liver disease or hemolysis.
Unconjugated bilirubin is a yellow pigment produced from the breakdown of old red blood cells. Normally, the liver converts this “indirect” bilirubin into a water‑soluble form that is excreted in stool. When the conversion process is overwhelmed, bilirubin builds up in the blood (hyperbilirubinemia). If levels climb above 20–25 mg/dL in a neonate, the pigment can penetrate the central nervous system, leading to permanent neurologic damage.
Because the injury is often irreversible, early detection and treatment of severe jaundice are crucial. Kernicterus was once a leading cause of infant mortality, but widespread use of phototherapy and newborn screening has dramatically reduced its incidence in high‑resource settings.[1] Mayo Clinic
Common Causes
Several conditions can precipitate the dangerously high bilirubin levels that lead to kernicterus. The most frequent causes in newborns, and notable adult/older‑child triggers, are listed below.
- Hemolytic disease of the newborn (HDN) – maternal‑blood‑type incompatibility (e.g., Rh or ABO) causing rapid red‑cell destruction.
- Physiologic newborn jaundice – normal increase in bilirubin due to immature liver enzymes, often exaggerated in pre‑term infants.
- Breast‑feeding jaundice – inadequate milk intake in the first days of life leading to dehydration and reduced bilirubin excretion.
- Breast‑milk jaundice – substances in breast milk that increase enterohepatic circulation of bilirubin, typically peaking in weeks 2‑3.
- Genetic enzyme deficiencies – G6PD deficiency, pyruvate kinase deficiency, or congenital dyserythropoietic anemia causing chronic hemolysis.
- Crigler‑Najjar syndrome (type I & II) – rare autosomal‑recessive disorder with absent or severely reduced UDP‑glucuronosyltransferase activity.
- Gilbert and Rotor syndromes – milder enzyme defects that can exacerbate jaundice in the presence of other stressors.
- Sepsis or severe infection – cytokine‑mediated impairment of hepatic bilirubin conjugation and increased hemolysis.
- Hypothyroidism – slows hepatic metabolism and can compound jaundice in newborns.
- Medications or toxins – certain drugs (e.g., sulfonamides, rifampin) or chemicals that displace bilirubin from albumin binding sites.
Associated Symptoms
Before irreversible neurologic injury occurs, infants with dangerously high bilirubin often display warning signs that may be subtle.
- Yellowing of the skin and sclera (jaundice) that spreads from the face downward.
- Lethargy, poor feeding, or difficulty waking for feeds.
- High‑pitched cry or “cheerful” crying despite illness.
- Hypotonia (floppy tone) or, conversely, hypertonia (stiffness) in the extremities.
- Arching of the back (opisthotonus) – a classic sign of acute bilirubin neurotoxicity.
- Seizure‑like activity or abnormal movements.
- Temperature instability, especially hypothermia.
When kernicterus progresses, permanent deficits may appear, such as:
- Auditory dysfunction (high‑frequency hearing loss).
- Movement disorders (cerebral palsy‑like spasticity, dystonia).
- Intellectual disability and developmental delay.
- Eye movement abnormalities (nystagmus, gaze palsy).
When to See a Doctor
Because the window for preventing permanent damage is narrow, parents and caregivers should act quickly if they notice any of the following:
- Jaundice that extends beyond the chest or abdomen in a newborn younger than 72 hours.
- Rapid increase in the yellow color of the skin or eyes.
- Baby is unusually sleepy, difficult to awaken, or refuses to feed.
- High‑pitched, inconsolable crying or sudden change in crying pattern.
- Any seizure‑like activity, tremors, or abnormal posturing.
- Temperatures below 36.5 °C (97.7 °F) or above 38 °C (100.4 °F) without an obvious cause.
- Family history of hemolytic disease, enzyme deficiency, or prior infant with severe jaundice.
If you suspect any of these, seek medical care immediately—preferably at an emergency department or urgent care facility equipped for newborn evaluation.
Diagnosis
Doctors combine clinical observation with laboratory and imaging studies to confirm kernicterus or assess risk.
1. Serum Bilirubin Measurement
- Total serum bilirubin (TSB) – primary screening test; values >20 mg/dL in term infants or >15 mg/dL in preterm infants are concerning.
- Direct (conjugated) vs. indirect (unconjugated) bilirubin – kernicterus is linked to extremely high indirect levels.
2. Blood‑type and Coombs Test
Determine if hemolytic disease of the newborn is present.
3. Complete Blood Count (CBC) and Reticulocyte Count
Assess for hemolysis or anemia.
4. Liver Function Tests (AST, ALT, GGT, ALP)
Rule out hepatic dysfunction as a contributing factor.
5. Neuroimaging
- Brain MRI – shows characteristic hyperintensity in the basal ganglia, thalamus, and brainstem on T1‑weighted images.
- Transcranial ultrasound – useful in unstable neonates; may reveal echogenic changes.
6. Auditory Brainstem Response (ABR) Testing
Early screening for bilirubin‑related hearing loss.
7. Clinical Scoring Tools
Risk‑assessment nomograms (e.g., Bhutani’s bilirubin nomogram) help decide when phototherapy or exchange transfusion is needed.[2] AAP
Treatment Options
The primary goal is to rapidly reduce serum bilirubin to safe levels and prevent further bilirubin crossing into the brain.
1. Phototherapy
- Uses blue‑green light (≈460 nm) to convert bilirubin into water‑soluble isomers that can be excreted without conjugation.
- Standard, intensive, or double‑surface devices are selected based on bilirubin level and infant weight.
- Typically the first‑line therapy for TSB ≥ 15–20 mg/dL (depends on age, gestation, and risk factors).
2. Exchange Transfusion
- Indicated when bilirubin levels exceed the exchange threshold (often >25 mg/dL in term infants) or if neurologic signs develop despite phototherapy.
- Blood is removed and replaced with donor, albumin‑rich blood, rapidly lowering bilirubin.
- Requires skilled neonatal intensive care unit (NICU) staff; carries risks of infection, electrolyte imbalance, and thrombocytopenia.
3. Intravenous Immunoglobulin (IVIG)
Used for immune‑mediated hemolysis (e.g., Rh incompatibility) to reduce hemolysis and bilirubin production.
4. Albumin Infusions
High‑dose albumin may displace bilirubin from binding sites, but evidence is limited; usually reserved for refractory cases.
5. Supportive Care
- Ensuring adequate hydration and nutrition (frequent feeds or IV fluids).
- Monitoring electrolytes, glucose, and temperature.
- Treating underlying infection or sepsis if present.
6. Long‑Term Management
If kernicterus has already caused neurologic injury, treatment focuses on rehabilitation:
- Physical, occupational, and speech therapy to address motor and developmental deficits.
- Audiology follow‑up and hearing aids or cochlear implants when needed.
- Early intervention programs and special‑education services.
Prevention Tips
Most cases of kernicterus are preventable with timely screening and appropriate management of jaundice.
- Early bilirubin screening – obtain a total serum bilirubin level before discharge for all newborns, and repeat at 24‑48 hours for high‑risk infants.
- Encourage frequent feeding – breast‑fed babies should nurse 8‑12 times per day to promote stooling and bilirubin excretion.
- Educate parents – teach how to recognize expanding jaundice and when to call the pediatrician.
- Maternal blood‑type testing – identify Rh incompatibility early; administer Rh immunoglobulin when indicated.
- Avoid medications that displace bilirubin – consult a clinician before giving sulfonamides, aspirin, or certain antibiotics to infants.
- Manage underlying hemolytic disorders – provide prophylactic folic acid, avoid oxidative stressors in G6PD‑deficient infants.
- Consider photo‑therapy at home – for mild to moderate jaundice, home phototherapy units (prescribed by a physician) can reduce readmission risk.
- Prompt treatment of infections – sepsis can exacerbate hyperbilirubinemia; early antibiotics reduce this risk.
Emergency Warning Signs
- Serum bilirubin >20 mg/dL in a term infant (or >15 mg/dL in a preterm) accompanied by any neurologic change.
- Decreased level of consciousness, unresponsiveness, or inability to wake for feeds.
- Seizure activity, rhythmic jerking, or abnormal posturing (e.g., opisthotonus).
- Sudden high‑pitched, inconsolable crying or loss of cry.
- Marked hypotonia or persistent floppiness.
- Persistent fever >38 °C (100.4 °F) or hypothermia <36 °C (96.8 °F) without obvious cause.
- Any sign of rapid bilirubin rise (increase >0.5 mg/dL per hour) after birth.
If any of these signs are present, call emergency services (911) or go to the nearest emergency department immediately. Early intervention can be life‑saving and may prevent permanent neurologic injury.
References:
- 1. Mayo Clinic. “Kernicterus (Bilirubin‑Induced Neurologic Dysfunction).” https://www.mayoclinic.org/diseases-conditions/kernicterus/
- 2. American Academy of Pediatrics. “Management of Hyperbilirubinemia in the Newborn Infant 35 or More Weeks of Gestation.” Pediatrics, 2022. https://pediatrics.aappublications.org/
- 3. NIH Neonatal Jaundice Guidelines. https://www.nichd.nih.gov/health/topics/jaundice
- 4. World Health Organization. “Prevention and Management of Neonatal Jaundice.” WHO Guidelines, 2021.
- 5. Cleveland Clinic. “Kernicterus – Causes, Symptoms, and Treatment.” https://my.clevelandclinic.org/health/diseases/